DocGo's shares have plummeted over 45% since mid-February, declining over 20% after reporting Q4 '24 on February 27th. The company has relied on contingencies such as COVID-19 testing and large contracts for a significant part of its revenues, much of which has now dried up. The company is transitioning to a new revenue model targeting Health Insurance Partnerships, aiming for more stable and predictable revenues. Yet, this space is highly competitive.
Motion Acquisition (DCGO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
DocGo, Inc (NASDAQ:DCGO ) Q4 2024 Results Conference Call February 27, 2025 5:00 PM ET Company Participants Mike Cole - VP of Investor Relations Lee Bienstock - Chief Executive Officer Norman Rosenberg - Chief Financial Officer Conference Call Participants Pito Chickering - Deutsche Bank Richard Close - Canaccord Genuity David Larsen - BTIG Aidan Conniff - Stifel Operator Good afternoon, ladies and gentlemen, and welcome to the DocGo Fourth Quarter and Full Year 2024 Earnings Call. At this time, all lines are in listen only mode.
DocGo Inc. (DCGO) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.06 per share a year ago.
DocGo (DCGO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
DocGo, Inc. (NASDAQ:DCGO ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Michael Cole - VP, IR Lee Bienstock - CEO Norman Rosenberg - CFO Conference Call Participants Pito Chickering - Deutsche Bank Ryan MacDonald - Needham Operator Welcome to DocGo, Inc. Third Quarter 2024 Earnings Call. [Operator Instructions].
DocGo Inc. (DCGO) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.05 per share a year ago.
DocGo Inc. (DCGO) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.07 per share. This compares to loss of $0.02 per share a year ago.
DocGo Inc. (NASDAQ:DCGO ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Mike Cole – Vice President, Investor Relations Lee Bienstock - Chief Executive Officer Norman Rosenberg - Chief Financial Officer Conference Call Participants Sarah James - Cantor Fitzgerald Mike Latimore - Northland Capital Markets David Larsen – BTIG Pito Chickering - Deutsche Bank David Grossman - Stifel Ryan MacDonald - Needam Richard Close - Canaccord Genuity Operator Good day everyone, and welcome to the DocGo Second Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DocGo Inc. ("DocGo" or "the Company") (NASDAQ:DCGO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.